Short answer
West Pharmaceutical Services (WST) filed its Q1 2026 10-Q quarterly report on Apr 23, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $845M (up 21.0% year over year) with net income of $139M.
Q1 2026 key financials · XBRL
- Revenue
- $845M
- +21.0% YoY
- Net income
- $139M
- +54.6% YoY
- Operating margin
- 21.0%
- Gross margin
- 35.1%
- EPS (diluted)
- $1.92
- +56.1% YoY
Source: XBRL data from the West Pharmaceutical Services (WST) Q1 2026 10-Q on SEC EDGAR. USD.
West Pharmaceutical Services Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Forward-looking results subject to uncertainties and risks cited in 2025 Annual Report and current Form 10-Q
Risk Factors
- No risk-factors section provided; supplied text covers share repurchases, trading plans, exhibits, and signatures
- New $1.0 billion repurchase program authorized in February 2026 with no expiration date
- Repurchases totaled 1,222,019 shares at $243.57 average through March 31, 2026
- CEO trading-plan disclosure covers acquisition of 83,616 shares through option exercise on February 4, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other West Pharmaceutical Services quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.